SE452460B - 3-/2-(dimetylamino)etyl/-n-metyl-1h-indol-5-metansulfonamid, en farmaceutisk komposition innehallande denna och ett forfarande for framstellning av foreningen - Google Patents

3-/2-(dimetylamino)etyl/-n-metyl-1h-indol-5-metansulfonamid, en farmaceutisk komposition innehallande denna och ett forfarande for framstellning av foreningen

Info

Publication number
SE452460B
SE452460B SE8503680A SE8503680A SE452460B SE 452460 B SE452460 B SE 452460B SE 8503680 A SE8503680 A SE 8503680A SE 8503680 A SE8503680 A SE 8503680A SE 452460 B SE452460 B SE 452460B
Authority
SE
Sweden
Prior art keywords
compound
formula
group
salt
solution
Prior art date
Application number
SE8503680A
Other languages
English (en)
Swedish (sv)
Other versions
SE8503680L (sv
SE8503680D0 (sv
Inventor
A W Oxford
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10564759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE452460(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SE8503680D0 publication Critical patent/SE8503680D0/xx
Publication of SE8503680L publication Critical patent/SE8503680L/xx
Publication of SE452460B publication Critical patent/SE452460B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE8503680A 1984-08-01 1985-08-01 3-/2-(dimetylamino)etyl/-n-metyl-1h-indol-5-metansulfonamid, en farmaceutisk komposition innehallande denna och ett forfarande for framstellning av foreningen SE452460B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848419575A GB8419575D0 (en) 1984-08-01 1984-08-01 Chemical compounds

Publications (3)

Publication Number Publication Date
SE8503680D0 SE8503680D0 (sv) 1985-08-01
SE8503680L SE8503680L (sv) 1986-02-02
SE452460B true SE452460B (sv) 1987-11-30

Family

ID=10564759

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8503680A SE452460B (sv) 1984-08-01 1985-08-01 3-/2-(dimetylamino)etyl/-n-metyl-1h-indol-5-metansulfonamid, en farmaceutisk komposition innehallande denna och ett forfarande for framstellning av foreningen

Country Status (42)

Country Link
US (1) US5037845A (fr)
JP (1) JPH0623197B2 (fr)
KR (1) KR930003759B1 (fr)
AT (1) AT386196B (fr)
AU (1) AU573878B2 (fr)
BE (1) BE903006A (fr)
CA (1) CA1241004A (fr)
CH (1) CH666026A5 (fr)
CZ (1) CZ280530B6 (fr)
DE (1) DE3527648A1 (fr)
DK (1) DK158942C (fr)
DO (1) DOP1989004759A (fr)
EC (1) ECSP941096A (fr)
EG (1) EG17283A (fr)
ES (6) ES8700234A1 (fr)
FI (1) FI78466C (fr)
FR (1) FR2568571B1 (fr)
GB (1) GB8419575D0 (fr)
GR (1) GR851850B (fr)
HK (1) HK33289A (fr)
HU (1) HU201738B (fr)
IE (1) IE58122B1 (fr)
IL (1) IL75986A (fr)
IS (1) IS1430B6 (fr)
IT (1) IT1207325B (fr)
JO (1) JO1379B1 (fr)
KE (1) KE3858A (fr)
LU (2) LU88266I2 (fr)
MA (1) MA20499A1 (fr)
MX (2) MX159672A (fr)
NL (2) NL188642C (fr)
NO (2) NO164653C (fr)
NZ (1) NZ212948A (fr)
PH (2) PH22850A (fr)
PL (1) PL146005B1 (fr)
PT (1) PT80900B (fr)
SE (1) SE452460B (fr)
SK (1) SK404191A3 (fr)
SU (1) SU1498386A3 (fr)
UA (1) UA6329A1 (fr)
ZA (1) ZA855818B (fr)
ZW (1) ZW12485A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270333A (en) * 1986-01-28 1993-12-14 Glaxo Group Limited Indole derivatives
US5935925A (en) * 1990-05-08 1999-08-10 Synaptic Pharmaceutical Corporation Methods of treating migraine and compounds useful for such methods
US5155218A (en) * 1990-05-08 1992-10-13 Neurogenetic Corporation Dna encoding human 5-ht1d receptors
GB9013845D0 (en) * 1990-06-21 1990-08-15 Glaxo Group Ltd Process
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9102579D0 (en) * 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
GB9101592D0 (en) * 1991-01-24 1991-03-06 Glaxo Group Ltd Compositions
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
AT399870B (de) * 1991-06-06 1995-08-25 Vita Invest Sa Verfahren zur herstellung von 3-(2-(dimethylamino)ethyl)-n-methyl-1h-indol-5- ethansulfonamid
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
ES2059236B1 (es) * 1992-06-18 1995-06-16 Imidex S A Procedimiento para la sintesis de la 3-(2-dimetilamino) etil)-n-metil-1h-indol-5-metanosulfonamida.
ES2055651B1 (es) * 1992-07-20 1995-03-01 Vita Invest Sa Procedimiento para la obtencion de nuevas amidinas derivadas de 3-aminoetilindoles.
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
AT399871B (de) * 1993-02-15 1995-08-25 Vita Invest Sa Verfahren zur herstellung von 2-carboxy-3-(2- (dimethylamino)ethyl)-n-methyl-1h-indol-5- methansulfonamid und dessen niederalkylestern
US5807571A (en) * 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
ES2084560B1 (es) * 1994-03-09 1997-01-16 Almirall Lab Procedimiento de preparacion de derivados el indol.
ES2079323B1 (es) * 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
CA2195107A1 (fr) * 1994-08-02 1996-02-15 Richard Alexander Jelley Derives de l'azetidine, de la pyrrolidine et de la piperidine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
WO1998011895A1 (fr) * 1996-09-18 1998-03-26 Eli Lilly And Company Methode de prevention de migraine
WO1998015545A1 (fr) * 1996-10-08 1998-04-16 Eli Lilly And Company Nouveaux agonistes de la serotonine 5-ht¿1f?
GB9714383D0 (en) * 1997-07-08 1997-09-10 Pfizer Ltd Improved process
US6416472B1 (en) 1997-11-06 2002-07-09 Edus Inc. Method and device for measuring cognitive efficiency
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
AT500063A1 (de) * 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
WO2003079972A2 (fr) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
NZ528377A (en) * 2001-03-27 2005-05-27 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
FR2827287B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060106227A1 (en) * 2002-06-13 2006-05-18 Dr Reddy's Laboratories Limited 3-'2-(Dimethylamino) ethyl!-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
WO2004056769A2 (fr) * 2002-12-20 2004-07-08 Ciba Specialty Chemicals Holding Inc. Synthèse d'amines et intermédiaires pour cette synthèse
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (fr) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Formes cristallines du sumatriptan, compositions pharmaceutiques et procedes
EP1626956A1 (fr) * 2003-05-12 2006-02-22 Potluri, Ramesh Babu Nouveau procede pour la preparation de derives d'indole
AU2004247076A1 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and NSAIDs
WO2004112723A2 (fr) * 2003-06-20 2004-12-29 Ronald Aung-Din Therapie locale pour le traitement des migraines, des claquages musculaires, des spasmes musculaires, de la spasticite et d'etats apparentes
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
WO2005123043A2 (fr) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations de sumatriptan absorbables au travers des membranes biologiques, et methodes de production et d'utilisation desdites formulations
KR20130136010A (ko) * 2005-04-13 2013-12-11 네우렉슨 인코포레이티드 Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물
WO2007070504A2 (fr) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Compositions orales liquides de sumatriptan stables et de gout agreable
JP5350219B2 (ja) * 2006-04-13 2013-11-27 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する１，５および３，６−置換インドール化合物
BRPI0715579A2 (pt) * 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US20090076121A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan
US20090163451A1 (en) * 2007-11-16 2009-06-25 Frank Porreca Methods for treating visceral pain
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
KR20100103799A (ko) * 2007-11-16 2010-09-28 네우렉슨 인코포레이티드 내장통을 치료하기 위한 인돌 화합물 및 방법
WO2009128089A2 (fr) * 2008-02-11 2009-10-22 Matrix Laboratories Limited Nouvelle forme de solvate de succinate de sumatriptan et procédé de préparation d'un sel de sumatriptan l'utilisant
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
WO2010005507A1 (fr) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Traitement neuro-affectif régional topique
WO2010046399A1 (fr) * 2008-10-22 2010-04-29 Novartis Ag Combinaisons pour le traitement de la migraine
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
DK2480197T3 (en) * 2009-09-25 2016-01-25 Reddys Lab Ltd Dr Compositions containing triptanforbindelser
JP5660817B2 (ja) * 2010-07-21 2015-01-28 高田製薬株式会社 スマトリプタンコハク酸塩を含有する内用液剤
CN102432520B (zh) * 2011-11-21 2013-10-09 山东新华制药股份有限公司 3-[2-（二甲氨基）乙基]-n-甲基吲哚-5-甲烷磺酰胺琥珀酸盐的制备方法
JP2018507262A (ja) 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE311728C (fr) *
US3322787A (en) * 1964-09-25 1967-05-30 Merck & Co Inc Alpha-hydrazino-beta-(3-indolyl) alkanoic acid derivatives
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
US4283410A (en) * 1978-06-15 1981-08-11 Miles Laboratories, Inc. 3-Amino or amido-2-(1H-indol-3-yl) propanoic acid derivatives
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
CH651551A5 (fr) * 1980-08-12 1985-09-30 Glaxo Group Ltd Derives de l'indole, leur preparation et compositions pharmaceutiques les contenant.
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
IT1171450B (it) * 1980-08-12 1987-06-10 Glaxo Group Ltd Composti eterociclici indolici, procedimento per produrli e composizioni farmaceutiche che li contengono
IT1170387B (it) * 1982-06-07 1987-06-03 Glaxo Group Ltd Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
GB8332434D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Production of chemical compounds
GB8332435D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU4568985A (en) 1986-02-06
SE8503680L (sv) 1986-02-02
FI852969A0 (fi) 1985-08-01
UA6329A1 (uk) 1994-12-29
DK351185A (da) 1986-02-02
AT386196B (de) 1988-07-11
ES557481A0 (es) 1988-02-16
SU1498386A3 (ru) 1989-07-30
ZW12485A1 (en) 1986-02-26
PH22850A (en) 1989-01-19
PH24117A (en) 1990-03-05
SE8503680D0 (sv) 1985-08-01
MX14221A (es) 1993-10-01
FI78466C (fi) 1989-08-10
SK277952B6 (en) 1995-09-13
ES557483A0 (es) 1988-02-16
KR860001788A (ko) 1986-03-22
NO164653C (no) 1990-11-07
HU201738B (en) 1990-12-28
MX159672A (es) 1989-08-02
NO853046L (no) 1986-02-03
HK33289A (en) 1989-04-28
IT8548435A0 (it) 1985-08-01
ES8801788A1 (es) 1988-02-16
SK404191A3 (en) 1995-09-13
CH666026A5 (fr) 1988-06-30
CZ280530B6 (cs) 1996-02-14
DK158942B (da) 1990-08-06
ZA855818B (en) 1986-04-30
NL8502171A (nl) 1986-03-03
BE903006A (fr) 1986-02-03
GR851850B (fr) 1985-11-26
ES552047A0 (es) 1987-12-16
KR930003759B1 (ko) 1993-05-10
ES8801204A1 (es) 1987-12-16
ES557480A0 (es) 1988-02-16
PL254800A1 (en) 1986-10-21
NL930065I1 (nl) 1993-09-01
HUT40077A (en) 1986-11-28
CZ404191A3 (en) 1993-04-14
NO164653B (no) 1990-07-23
ES8801789A1 (es) 1988-02-16
PT80900A (en) 1985-09-01
IT1207325B (it) 1989-05-17
PT80900B (pt) 1987-12-30
NL930065I2 (nl) 1993-10-01
ECSP941096A (es) 1995-01-16
ES8801790A1 (es) 1988-02-16
IL75986A (en) 1989-02-28
DE3527648C2 (fr) 1993-08-26
ATA226685A (de) 1987-12-15
CA1241004A (fr) 1988-08-23
FR2568571B1 (fr) 1988-09-23
JPS6147464A (ja) 1986-03-07
GB8419575D0 (en) 1984-09-05
KE3858A (en) 1989-06-02
ES545810A0 (es) 1986-10-16
LU86032A1 (fr) 1986-02-18
ES8801900A1 (es) 1988-03-01
IS3034A7 (is) 1986-02-02
JO1379B1 (en) 1986-11-30
FI852969L (fi) 1986-02-02
IS1430B6 (is) 1990-07-16
FI78466B (fi) 1989-04-28
DOP1989004759A (es) 1999-02-06
MA20499A1 (fr) 1986-04-01
NL188642C (nl) 1992-08-17
PL146005B1 (en) 1988-12-31
ES8700234A1 (es) 1986-10-16
DE3527648A1 (de) 1986-02-13
US5037845A (en) 1991-08-06
IE58122B1 (en) 1993-07-14
NZ212948A (en) 1989-05-29
IE851918L (en) 1986-02-01
LU88266I2 (fr) 1994-02-03
NO1994023I1 (no) 1994-11-09
EG17283A (en) 1992-06-30
FR2568571A1 (fr) 1986-02-07
DK351185D0 (da) 1985-08-01
JPH0623197B2 (ja) 1994-03-30
DK158942C (da) 1991-01-21
IL75986A0 (en) 1985-12-31
ES557482A0 (es) 1988-03-01
AU573878B2 (en) 1988-06-23

Similar Documents

Publication Publication Date Title
SE452460B (sv) 3-/2-(dimetylamino)etyl/-n-metyl-1h-indol-5-metansulfonamid, en farmaceutisk komposition innehallande denna och ett forfarande for framstellning av foreningen
GB2162522A (en) An indole derivative
US4636521A (en) 3 amino alkyl indoles for use in treating migraine
EP0147107B1 (fr) Derivés du noyau indole
AU780190B2 (en) Aminoalkoxy carbazoles for the treatment of CNS diseases
JPH0148896B2 (fr)
JPS62228056A (ja) 化学的化合物
EP0225726B1 (fr) Dérivés de l&#39;indole
US5633276A (en) Indoline derivatives, method of preparation and use
IE51493B1 (en) Heterocyclic compounds
KR900004385B1 (ko) 카복사미드 유도체 및 그의 제조방법
FR2574793A1 (fr) Composes derives d&#39;indole, compositions pharmaceutiques les contenant et procede pour leur preparation
US4870096A (en) 5-substituted 3-aninoalkyl indoles
AU600813B2 (en) Aliphatic carboxamides
NL8700027A (nl) Chemische verbindingen.
US4898863A (en) Heterocyclic carboxamides
US4980368A (en) Tryptamine compounds, and methods of cerebrovascular treatment therewith
NL8701372A (nl) Indoolderivaten, werkwijze ter bereiding daarvan alsmede farmaceutische preparaten die deze derivaten als actieve component bevatten.
US4876267A (en) 5-Aminosulphoryl substituted indole derivatives
AU609067B2 (en) Compounds useful as intermediates for the production of substituted 1-pyridyloxy-3-indolyalkylamino-2- propanols

Legal Events

Date Code Title Description
SPCF Application for supplementary protection certificate filed

Free format text: 8503680

NAL Patent in force

Ref document number: 8503680-4

Format of ref document f/p: F

SPCG Supplementary protection certificate granted

Free format text: 9490026, 911018, EXPIRES: 20060515

SPCG Supplementary protection certificate granted

Free format text: 9490026, 911018, EXPIRES: 20061017

NUG Patent has lapsed